Abstract
Differential diagnosis of AD is still a challenge due to overlapping features with other types of dementia. Biomarkers for the differential diagnosis of AD can improve the diagnostic value of the disease and ensure an appropriate treatment of patients. The aim of this study was to evaluate the potential of two neo-epitope fragments of Tau as serum biomarkers for differential diagnosis of AD.
The neo-epitope fragments of Tau were assessed in a cross-sectional cohort of subjects with AD, MCI, other dementias or subjects with non-dementia related memory complaints. The two Tau neo-epitope fragments were an ADAM10-generated fragment (Tau-A) and a caspase-3-generated fragment (Tau-C). The serum levels of the fragments were measured by two competitive ELISAs detecting Tau-A and Tau-C, respectively.
Tau-A and Tau-C were able to separate subjects with AD and MCI from those with other dementias (p < 0.0042 and p < 0.05), and Tau-A could also discriminate between AD and MCI patients and subjects with non-dementia related memory complaints (p < 0.05). Tau-A showed a significantly greater discrimination between AD and MCI subjects and patients with other dementias when compared to CSF biomarkers t-Tau and p-Tau. The ability of Tau-A to differentiate between AD and MCI from other dementias was comparable with CSF Aβ1-42, t-Tau/Aβ1-42 and p-Tau/Aβ1-42. The separation between the diagnostic groups was significantly improved when the CSF biomarkers as well as age and BMI were used in combination with Tau-A (AUC = 0.87, 95% CI: 0.75-0.94) (p < 0.0001). In conclusion, this study shows that a neoepitope fragment of Tau detected in serum can provide guidance on the differential diagnosis of AD.
Keywords: Alzheimer’s disease, differential diagnosis, serum biomarkers, tau fragments.
Current Alzheimer Research
Title:Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease
Volume: 12 Issue: 9
Author(s): D. Inekci, K. Henriksen, T. Linemann, M.A. Karsdal, A. Habib, C. Bisgaard, F.B. Eriksen and O.J. Vilholm
Affiliation:
Keywords: Alzheimer’s disease, differential diagnosis, serum biomarkers, tau fragments.
Abstract: Differential diagnosis of AD is still a challenge due to overlapping features with other types of dementia. Biomarkers for the differential diagnosis of AD can improve the diagnostic value of the disease and ensure an appropriate treatment of patients. The aim of this study was to evaluate the potential of two neo-epitope fragments of Tau as serum biomarkers for differential diagnosis of AD.
The neo-epitope fragments of Tau were assessed in a cross-sectional cohort of subjects with AD, MCI, other dementias or subjects with non-dementia related memory complaints. The two Tau neo-epitope fragments were an ADAM10-generated fragment (Tau-A) and a caspase-3-generated fragment (Tau-C). The serum levels of the fragments were measured by two competitive ELISAs detecting Tau-A and Tau-C, respectively.
Tau-A and Tau-C were able to separate subjects with AD and MCI from those with other dementias (p < 0.0042 and p < 0.05), and Tau-A could also discriminate between AD and MCI patients and subjects with non-dementia related memory complaints (p < 0.05). Tau-A showed a significantly greater discrimination between AD and MCI subjects and patients with other dementias when compared to CSF biomarkers t-Tau and p-Tau. The ability of Tau-A to differentiate between AD and MCI from other dementias was comparable with CSF Aβ1-42, t-Tau/Aβ1-42 and p-Tau/Aβ1-42. The separation between the diagnostic groups was significantly improved when the CSF biomarkers as well as age and BMI were used in combination with Tau-A (AUC = 0.87, 95% CI: 0.75-0.94) (p < 0.0001). In conclusion, this study shows that a neoepitope fragment of Tau detected in serum can provide guidance on the differential diagnosis of AD.
Export Options
About this article
Cite this article as:
Inekci D., Henriksen K., Linemann T., Karsdal M.A., Habib A., Bisgaard C., Eriksen F.B. and Vilholm O.J., Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease, Current Alzheimer Research 2015; 12 (9) . https://dx.doi.org/10.2174/1567205012666150710111211
DOI https://dx.doi.org/10.2174/1567205012666150710111211 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Mechanisms of Glucocorticoids Action: From Basic Research to Clinical Implications
Current Immunology Reviews (Discontinued) Recent Multi-target Approaches on the Development of Anti- Alzheimer's Agents Integrating Metal Chelation Activity
Current Medicinal Chemistry STAT3 and Its Phosphorylation are Involved in HIV-1 Tat-Induced Transactivation of Glial Fibrillary Acidic Protein
Current HIV Research Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Cognitive, Psychological and Psychiatric Effects of Ionizing Radiation Exposure
Current Medicinal Chemistry Docosahexaenoic Acid-Containing Phospholipids and Triglycerides Based Nutritional Supplements
Recent Patents on Food, Nutrition & Agriculture Platelet Resistance to Antiplatelet Drugs
Recent Patents on Cardiovascular Drug Discovery Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors
Current Bioinformatics Influence of Genetic Background on Apathy-Like Behavior in Triple Transgenic AD Mice
Current Alzheimer Research Forkhead Transcription Factors: Formulating a FOXO Target for Cognitive Loss
Current Neurovascular Research Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets Molecular Mechanisms of Thiamine Utilization.
Current Molecular Medicine Genetic Modifications of Icosahedral Plant Virus-based Nanoparticles for Vaccine and Immunotherapy Applications
Current Protein & Peptide Science Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) A Molecular Bridge: Connecting Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets In Silico Ligand-Receptor Docking of Potentially Selective Butyrylcholinesterase Inhibitors Structurally Related to the Marine Natural Product Debromoflustramine B
Medicinal Chemistry Centenarian Offspring: A Model for Understanding Longevity
Current Vascular Pharmacology The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target
Current Neuropharmacology Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry η-Secretase: Reduction of Amyloid Precursor Protein η-Site Cleavage in Alzheimers Disease
Current Alzheimer Research